Prognostic Influence of Pre-Operative C-Reactive Protein in Node-Negative Breast Cancer Patients

Isabel Sicking1, Karolina Edlund2, Eva Wesbuer1, Veronika Weyer3, Marco J. Battista1, Antje Lebrecht1, Christine Solbach1, Marianna Grinberg4, Johannes Lotz2, Gerald Hoffmann1, Jörg Rahnenführer4, Jan G. Hengstler2*, Marcus Schmidt1**

1 Department of Obstetrics and Gynecology, Johannes Gutenberg University, Mainz, Germany, 2 Leibniz Research Centre for Working Environment and Human Factors (IfADo), Dortmund University of Technology, Dortmund, Germany, 3 Institute of Medical Biometry, Epidemiology and Informatics (IMBEI), Johannes Gutenberg University, Mainz, Germany, 4 Department of Statistics, Dortmund University of Technology, Dortmund, Germany, 5 Institute for Clinical Chemistry, Johannes Gutenberg University, Mainz, Germany

Abstract

The importance of inflammation is increasingly noticed in cancer. The aim of this study was to analyze the prognostic influence of pre-operative serum C-reactive protein (CRP) in a cohort of 148 lymph node-negative breast cancer patients. The prognostic significance of CRP level for disease-free survival (DFS), metastasis-free survival (MFS) and overall survival (OS) was evaluated using univariate and multivariate Cox regression, also including information on age at diagnosis, tumor size, tumor grade, estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status, proliferation index (Ki67) and molecular subtype, as well as an assessment of the presence of necrosis and inflammation in the tumor tissue. Univariate analysis showed that CRP, as a continuous variable, was significantly associated with DFS (P = 0.002, hazard ratio [HR] = 1.04, 95% confidence interval [CI] = 1.02–1.07) and OS (P = 0.036, HR = 1.03, 95% CI = 1.00–1.06), whereas a trend was observed for MFS (P = 0.111). In the multivariate analysis, CRP retained its significance for DFS (P = 0.033, HR = 1.01, 95% CI = 1.00–1.07) as well as OS (P = 0.023, HR = 1.03, 95% CI = 1.00–1.06), independent of established prognostic factors. Furthermore, large-scale gene expression analysis by Affymetrix HG-U133A arrays was performed for 72 (48.6%) patients. The correlations between serum CRP and gene expression levels in the corresponding carcinoma of the breast were assessed using Spearman’s rank correlation, controlled for false-discovery rate. No significant correlation was observed between CRP level and gene expression indicative of an ongoing local inflammatory process. In summary, pre-operatively elevated CRP levels at the time of diagnosis were associated with shorter DFS and OS independent of established prognostic factors in node-negative breast cancer, supporting a possible link between inflammation and prognosis in breast cancer.

Introduction

The microenvironment of solid tumors is often rich in inflammatory cells which have appeared as essential players in the tumorigenic process [1]. A protective role of the immune system, especially in early stages of tumorigenesis, has become evident and a link between immune cell-infiltration and better prognosis has been described in various cancer types [2–6]. On the other hand, the immune system is known to be able to promote cancer initiation and progression and the causal relationship between chronic inflammation within the local tissue environment and cancer has received increased attention in recent years, leading up to the concept of cancer-related inflammation as an emerging hallmark of cancer [7].

Accordingly, a systemic inflammatory response as shown by an elevated concentration of circulating C-reactive protein (CRP) in peripheral blood, has frequently been associated with increased incidence as well as worse outcome in numerous types of cancer, e.g. gastro-oesophageal cancer, non-small cell lung cancer and prostate cancer [8–11]. CRP is a non-specific acute-phase protein that rises on acute infection as well as tissue trauma, chronic inflammatory disease, myocardial infarction, surgery and cancer. It is secreted primarily by hepatocytes in response to cytokine stimulation by for instance IL-1, IL-6 and TNF-alpha [12]. A recent meta-analysis underscored that CRP, as a biomarker of inflammation, is related to impaired outcome also in breast cancer patients [13]. However, this association was not confirmed by others [14,15]. Only few studies have examined the impact of pre-operative CRP levels on breast cancer prognosis, thus far with mixed results [16–20].

The association between CRP level and breast cancer survival has until now been examined mainly in patients with adjuvant systemic treatment. Therefore, the aim of the present study was to analyze the influence of pre-operative CRP level in an untreated...
Table 1. Clinicopathological characteristics for node-negative breast cancer patients.

|                               | n  | %  |
|-------------------------------|----|----|
| **Total number of patients**  | 148| 100.0|
| **C-reactive protein (CRP)**  |    |    |
| Elevated (>5mg/l)             | 31 | 20.9|
| Normal (≤5mg/l)               | 117| 79.1|
| **Tumor size**                |    |    |
| ≤2cm                          | 105| 70.9|
| >2cm                          | 43 | 29.1|
| **Tumor grade**               |    |    |
| Grade I                       | 40 | 27.0|
| Grade II                      | 84 | 56.8|
| Grade III                     | 24 | 16.2|
| **Age at diagnosis**          |    |    |
| <50 years                     | 29 | 19.6|
| ≥50 years                     | 119| 80.4|
| **Estrogen receptor status**  |    |    |
| ER positive                   | 128| 86.5|
| ER negative                   | 17 | 11.5|
| Missing data                  | 3  | 2.0 |
| **Progesterone receptor status** |     |    |
| PR positive                   | 33 | 22.3|
| PR negative                   | 112| 75.7|
| Missing data                  | 3  | 2.0 |
| **HER2 status**               |    |    |
| HER2 positive                 | 16 | 10.8|
| HER2 negative                 | 129| 87.2|
| Missing data                  | 3  | 2.0 |
| **Ki67**                      |    |    |
| ≤20%                          | 94 | 63.5|
| >20%                          | 43 | 29.1|
| Missing data                  | 11 | 7.4 |
| **Molecular subtype**         |    |    |
| Luminal A                     | 86 | 58.1|
| Luminal B                     | 24 | 16.2|
| Basal-like                    | 13 | 8.8 |
| HER2+                         | 16 | 10.8|
| Missing data                  | 9  | 6.1 |
| **Local recurrence**          |    |    |
| Yes                           | 10 | 6.8 |
| No                            | 138| 93.2|
| **Metastasis**                |    |    |
| Yes                           | 20 | 13.5|
| No                            | 128| 86.5|
| **Cause of death**            |    |    |
| Breast cancer                 | 13 | 8.8 |
| Other                         | 21 | 14.2|
| Alive at last follow-up       | 114| 77.0|
| **Necrosis**                  |    |    |
| Absent                        | 110| 74.3|
| Present                       | 48 | 25.7|
| **Inflammation**              |    |    |

CRP in Breast Cancer Patients
cohort of lymph node-negative breast cancer patients in relation to survival and established prognostic factors. Furthermore, we wanted to elucidate potential associations between pre-operative serum CRP and genes expressed in corresponding breast cancer specimen.

Materials and Methods

Patient cohort
There were three main eligibility criteria (i) node-negative breast cancer (ii) no systemic treatment in the adjuvant setting (iii) availability of CRP measurement. The initial study cohort consisted of 420 node-negative breast cancer patients, treated at the Department of Obstetrics and Gynecology at Johannes Gutenberg University Mainz between the years 1985 and 2004. Of these 420 patients, pre-operative CRP status was available for 148 individuals treated by surgical tumor resection, either modified radical mastectomy (n = 43; 29.1%) or breast conserving surgery followed by irradiation (n = 105; 70.9%), who did not receive systemic therapy in the adjuvant setting. The median age at diagnosis of the patients was 62 years (range 40 to 90 years). The mean follow-up time was 113 months. All patients provided their informed consent before study inclusion.

Information on tumor size (pT stage) as well as presence of necrosis or inflammation in the tumor was collected from the corresponding pathology report of the Gynecological Pathology Division”. From the breast cancer database [21], information on about of age at diagnosis, histological tumor grade, which was assigned according to Elston and Ellis [22], estrogen receptor (ER), progesterone receptor (PR) status and human epidermal growth factor receptor 2 (HER2) status and proliferation index (Ki67) were obtained (Table 1). Immunohistochemical analyses for ER, PR, HER2 and Ki-67 were performed on 4-μm-thick sections according to standard procedures. Briefly, serial sections of formalin-fixed and paraffin-embedded tumor tissues were stained with a monoclonal ER antibody (clone 1D5, Dako, Glostrup, Denmark), a monoclonal PR antibody (clone PgR 636, Dako), a monoclonal Ki-67 antibody (clone MIB-1, Dako, Glostrup, Denmark) as well as a polyclonal HER2 antibody (A0485, Dako, Glostrup, Denmark). HER2 was scored from 0 to 3+ according to the well-published manufacturer’s instructions. HER2 3+ tumors were considered HER2 positive. All HER2 2+ cases were confirmed by Fluorescence in-situ hybridization (FISH) using a dual-color probe (DakoCytomation) containing a spectrum orange-labeled HER-2HER2 gene (17q11.2-q12) probe and a spectrum green-labeled centromere control for chromosome 17 (17q11.1-q11.1). HER2 2+ tumors with HER2 amplification were finally considered HER2 positive. ER and PR was analyzed as percentage of all tumor cells and any nuclear expression >0 was considered positive. Ki67 expression in more than 20% of nuclei was considered as high expression (highly proliferative) and a percentage ≤20% was defined as low expression. Building on these variables, we calculated molecular subtypes: Luminal A (ER+ and/or PR+, HER2−, Ki67≤20%), Luminal B (ER+ and/or PR−, HER2−, Ki67≥20%), Basal-like (ER− and PR−, HER2−), and HER2+ (ER+/−, PR+/−, HER2+).

Gene expression array data from matched tumor tissue, analyzed by Affymetrix GeneChip Human Genome U133A arrays, was available for a subset of patients (n = 72) as previously described [2]. Raw.cel files, MAS 5.0 processed data and patient data have been deposited in National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) and are accessible through GEO Series accession no. GSE11121. We documented death from cancer or from other reasons unrelated to breast cancer and recurrence of disease, which include metastasis and local relapse. 13 (8.8%) patients died from breast cancer, 21 (14.2%) patients died from causes unrelated to breast cancer, 114 (77.0%) patients were alive at the date of last follow-up, 10 (6.8%) patients remained disease free and 20 (15.3%) developed distant metastasis. Patients who died from other reasons were censored from the survival analysis at the date of death. All participants provided written informed consent which was documented in the patient file. This study as well as the consent procedure was approved by the ethical review board of the medical association of Rhineland-Palatinate. All clinical investigations were conducted according to the principles expressed in the Declaration of Helsinki. The manuscript was prepared in agreement with the reporting recommendations for tumor marker reporting studies [23]. Ethical standards: The experiments comply with the current laws of Germany.

C-reactive protein
A 10-mL blood sample was collected the day before surgery. The sample was processed within 3 hours of collection. During the period of observation, the method of CRP determination changed once in 1992 from a nephelometric to a turbidimetric assay (Behring Diagnostics, Marburg, Germany and Boehringer Mannheim/Roche Diagnostics, Mannheim, Germany, respectively). The assays were performed following the manufacturer’s instructions on the BN-systems (Behring Diagnostics, Marburg, Germany) and the Hitachi 717/747/917 (Boehringer Mannheim/Roche Diagnostics, Mannheim, Germany) automated analyzers, respectively. According to the methodological progress, a wide range CRP assays was introduced in the late 90s/early 2000s. Since then, a measuring range of 0.1–300 mg/l was used. During the whole period, the upper limit of normal was 5 mg/l for all assays used. Intra- and inter-assay imprecision was less than 5% for CRP. Control materials were used for running each assay for quality control purposes.

Statistical analysis
To evaluate the association between pre-operative CRP level and established prognostic factors such as age, tumor size, tumor grade, ER, PR and HER2 status, proliferation index (Ki67) and molecular subtype with survival time, uni- and multivariate Cox regression analyses were performed. The internal stability of the models was tested by bootstrap resampling [24–27]. Briefly, new data sets with the same size of the original one were created by

| Table 1. Cont. | n | % |
|----------------|---|---|
| Absent         | 98 | 66.2 |
| Present        | 50 | 33.8 |

doi:10.1371/journal.pone.0111306.t001
Table 2. Univariate Cox regression analysis for disease-free survival (DFS), metastasis-free survival (MFS) and overall survival (OS).

|                     | DFS                |                     | MFS                |                     | OS                |                     |
|---------------------|--------------------|---------------------|--------------------|---------------------|-------------------|---------------------|
|                     | HR     | CI       | p-value | HR     | CI       | p-value | HR     | CI       | p-value |
| CRP                 | 1.04   | 1.02–1.07 | 0.002  | 1.03   | 0.99–1.07 | 0.110  | 1.03   | 1.00–1.06 | 0.036   |
| Age at diagnosis    |                    |                     |                    |                    |                   |                     |
| ≥ 50 years          | ref                |                     |                    |                    |                   |                     |
| < 50 years          | 0.41   | 0.18–0.93 | 0.032  | 0.29   | 0.12–0.71 | 0.006  | 1.29   | 0.53–3.12 | 0.575   |
| Tumor size          |                    |                     |                    |                    |                   |                     |
| ≤ 2cm               | ref                |                     |                    |                    |                   |                     |
| > 2cm               | 2.23   | 1.00–4.98 | 0.050  | 1.76   | 0.72–4.31 | 0.216  | 2.03   | 1.03–3.99 | 0.041   |
| Tumor grade         |                    |                     |                    |                    |                   |                     |
| I–II                | ref                |                     |                    |                    |                   |                     |
| III                 | 3.78   | 1.65–8.65 | 0.002  | 4.00   | 1.63–9.80 | 0.002  | 3.12   | 1.51–6.46 | 0.002   |
| ER status           |                    |                     |                    |                    |                   |                     |
| Negative            | ref                |                     |                    |                    |                   |                     |
| Positive            | 0.42   | 0.16–1.12 | 0.083  | 1.05   | 0.24–4.52 | 0.950  | 0.55   | 0.23–1.34 | 0.190   |
| PR status           |                    |                     |                    |                    |                   |                     |
| Negative            | ref                |                     |                    |                    |                   |                     |
| Positive            | 0.46   | 0.20–1.05 | 0.066  | 0.86   | 0.31–2.38 | 0.777  | 0.56   | 0.27–1.13 | 0.106   |
| HER2 status         |                    |                     |                    |                    |                   |                     |
| Negative            | ref                |                     |                    |                    |                   |                     |
| Positive            | 3.29   | 1.30–8.31 | 0.012  | 4.15   | 1.59–10.81 | 0.004  | 2.22   | 0.96–5.12 | 0.061   |
| Proliferation       |                    |                     |                    |                    |                   |                     |
| Ki67≤20%            | ref                |                     |                    |                    |                   |                     |
| Ki67>20%            | 2.17   | 0.96–4.93 | 0.063  | 1.70   | 0.68–4.23 | 0.253  | 1.58   | 0.78–3.20 | 0.203   |
| Necrosis            |                    |                     |                    |                    |                   |                     |
| Absent              | ref                |                     |                    |                    |                   |                     |
| Present             | 1.40   | 0.60–3.27 | 0.440  | 1.86   | 0.76–4.56 | 0.173  | 1.21   | 0.59–2.50 | 0.604   |
| Inflammation        |                    |                     |                    |                    |                   |                     |
| Absent              | ref                |                     |                    |                    |                   |                     |
| Present             | 1.15   | 0.50–2.62 | 0.743  | 0.82   | 0.31–2.13 | 0.682  | 1.20   | 0.60–2.39 | 0.614   |
| Molecular subtype   |                    |                     |                    |                    |                   |                     |
| Luminal A           | ref                |                     |                    |                    |                   |                     |
| Luminal B           | 0.91   | 0.26–3.28 | 0.890  | 1.14   | 0.31–4.21 | 0.843  | 1.02   | 0.37–2.77 | 0.976   |
| Basal-like          | 3.16   | 1.00–9.97 | 0.049  | 1.79   | 0.39–3.80 | 0.457  | 2.05   | 0.68–6.14 | 0.200   |
| HER2-like           | 3.63   | 1.34–9.85 | 0.011  | 4.33   | 1.54–12.20 | 0.005  | 2.50   | 1.03–6.11 | 0.044   |

HR: Hazard Ratio; CI: 95% Confidence Interval; Luminal A: ER+ and/or PR+, HER2--; Ki67≤20%; Luminal B: ER+ and/or PR+, HER2−, Ki67>20%; Basal-like: ER− and PR−, HER2−; HER2: ER+/−, PR+/−, HER2+. doi:10.1371/journal.pone.0111306.t002
Results

The pre-operatively assessed CRP level in peripheral blood was in the majority of patients (79.1%) within the normal reference interval, conventionally defined as ≤5 mg/l, while a subset of patients (20.9%) displayed an elevated CRP level (>5 mg/l) (Table 1).

Initially, univariate Cox regression analysis was performed to assess the impact on survival time of pre-operative CRP level, age at diagnosis, tumor size, tumor grade, ER, PR and HER2 status, cell tumor infiltration, tumor cell proliferation and estrogen receptor positivity [2] was assessed using Spearman’s rank correlation coefficient. Additionally, potential correlations between pre-operative CRP level and mRNA expression level for all probe sets on the Affymetrix HG-U133A array were assessed, with the false discovery rate adjusted to 0.05 according to Benjamini and Yekutieli. All P values were two sided. Since, except for the correlations between CRP and Affymetrix probe sets, no correction for multiple testing was performed, all results were interpreted as explorative. Statistical analyses were performed using the freely available statistical computing language R 3.0.1.

CRP in Breast Cancer Patients

PLOS ONE | www.plosone.org 5 October 2014 | Volume 9 | Issue 10 | e111306

Figure 1. Association of CRP with survival in node-negative breast cancer (n = 148). CRP dichotomized using values above upper limit normal (>5 mg/l, n = 31) shows no significant association with disease-free survival (A), metastasis-free survival (B) and overall survival (C), respectively. The numbers below the diagrams represent patients at risk at the time point indicated on the x-axis.

doi:10.1371/journal.pone.0111306.g001

random bootstraps from the original data set followed by the same Cox regression. To avoid potential pitfalls of dichotomization of prognostic factors with concomitant loss of test power [28–30] we used the prognostic factors in our multivariate Cox regression model as continuous variables. Survival rates were calculated according to the Kaplan-Meier method and survival times were compared with the Log-rank test. Disease-free survival (DFS) was specified as the time between date of surgery and the date of local or regional or metastatic recurrence. Breast cancer-related death or last follow-up. Metastasis-free survival (MFS) was defined as the time between date of surgery and diagnosis of distant metastasis. Overall survival (OS) was defined as the time between the date of surgery and the date of death. The Wilcoxon rank-sum test was applied to identify significant correlations between CRP level and clinical variables. A potential correlation between pre-operative CRP level and expression of metagenes representative of T- and B-cell tumor infiltration, tumor cell proliferation and estrogen receptor positivity [2] was assessed using Spearman’s rank correlation coefficient. Additionally, potential correlations between pre-operative CRP level and gene expression level for all probe sets on the Affymetrix HG-U133A array were assessed, with the false discovery rate adjusted to 0.05 according to Benjamini and Yekutieli. All P values were two sided. Since, except for the correlations between CRP and Affymetrix probe sets, no correction for multiple testing was performed, all results were interpreted as explorative. Statistical analyses were performed using the freely available statistical computing language R 3.0.1.

CRP in Breast Cancer Patients

PLOS ONE | www.plosone.org 5 October 2014 | Volume 9 | Issue 10 | e111306

Figure 1. Association of CRP with survival in node-negative breast cancer (n = 148). CRP dichotomized using values above upper limit normal (>5 mg/l, n = 31) shows no significant association with disease-free survival (A), metastasis-free survival (B) and overall survival (C), respectively. The numbers below the diagrams represent patients at risk at the time point indicated on the x-axis.

doi:10.1371/journal.pone.0111306.g001

random bootstraps from the original data set followed by the same Cox regression. To avoid potential pitfalls of dichotomization of prognostic factors with concomitant loss of test power [28–30] we used the prognostic factors in our multivariate Cox regression model as continuous variables. Survival rates were calculated according to the Kaplan-Meier method and survival times were compared with the Log-rank test. Disease-free survival (DFS) was specified as the time between date of surgery and the date of local or regional or metastatic recurrence. Breast cancer-related death or last follow-up. Metastasis-free survival (MFS) was defined as the time between date of surgery and diagnosis of distant metastasis. Overall survival (OS) was defined as the time between the date of surgery and the date of death. The Wilcoxon rank-sum test was applied to identify significant correlations between CRP level and clinical variables. A potential correlation between pre-operative CRP level and expression of metagenes representative of T- and B-cell tumor infiltration, tumor cell proliferation and estrogen receptor positivity [2] was assessed using Spearman’s rank correlation coefficient. Additionally, potential correlations between pre-operative CRP level and mRNA expression level for all probe sets on the Affymetrix HG-U133A array were assessed, with the false discovery rate adjusted to 0.05 according to Benjamini and Yekutieli. All P values were two sided. Since, except for the correlations between CRP and Affymetrix probe sets, no correction for multiple testing was performed, all results were interpreted as explorative. Statistical analyses were performed using the freely available statistical computing language R 3.0.1.

CRP in Breast Cancer Patients

PLOS ONE | www.plosone.org 5 October 2014 | Volume 9 | Issue 10 | e111306

Figure 1. Association of CRP with survival in node-negative breast cancer (n = 148). CRP dichotomized using values above upper limit normal (>5 mg/l, n = 31) shows no significant association with disease-free survival (A), metastasis-free survival (B) and overall survival (C), respectively. The numbers below the diagrams represent patients at risk at the time point indicated on the x-axis.

doi:10.1371/journal.pone.0111306.g001
Table 3. Multivariate Cox regression analysis for disease-free survival (DFS), metastasis-free survival (MFS) and overall survival (OS).

|          | DFS          | MFS          | OS           |
|----------|--------------|--------------|--------------|
|          | HR | CI | p-value | HR | CI | p-value | HR | CI | p-value |
| CRP      | 1.03 | 1.00–1.07 | 0.033 | 1.01 | 0.98–1.05 | 0.469 | 1.03 | 1.00–1.06 | 0.023 |
| $\geq 50$ years | 0.41 | 0.17–1.02 | 0.055 | 0.29 | 0.11–0.75 | 0.011 | 0.82 | 0.38–1.96 | 0.662 |
| $< 2$ cm | 2.47 | 1.06–5.76 | 0.036 | 2.11 | 0.81–5.53 | 0.128 | 1.08 | 0.42–2.76 | 0.833 |
| Luminal A | 0.58 | 0.13–2.64 | 0.483 | 0.83 | 0.16–4.15 | 0.815 | 0.80 | 0.12–4.93 | 0.813 |
| Basal-like | 2.13 | 0.52–8.70 | 0.290 | 1.24 | 0.27–5.52 | 0.742 | 0.72 | 0.18–2.95 | 0.633 |
| HER2-like | 2.12 | 0.59–7.55 | 0.247 | 2.26 | 0.73–6.12 | 0.275 | 0.72 | 0.18–2.95 | 0.633 |

HR: Hazard Ratio; CI: 95% Confidence Interval; Luminal A: ER and/or PR+, HER2−, Ki67+; Luminal B: ER and/or PR+, HER2−, Ki67+; Basal-like: ER and PR−; HER2−; HER2+: ER−/PR−/HER2+; $^{2}$ Significant at $\alpha = 0.05$.

Discussion

Prognostic factors for breast cancer patients at the time of diagnosis are today primarily based on clinicopathological characteristics, such as tumor size, axillary lymph node status, and histological differentiation grade, together with estrogen receptor (ER) and epidermal growth factor receptor 2 (HER2) status. Improved prognostication is necessary to decide whether adjuvant chemotherapy is required, in particular for patients with positive hormone receptor status and for node-negative patients [31]. While commercially available gene expression-based prognostic assays, such as MammaPrint [32], Oncotype DX [33] and EndoPredict [34] have proven effective, these are not yet established in clinical routine for every patient. Prognostic biomarkers based on easily implementable non-invasive procedures, which are used in clinical routine, would potentially be of benefit to larger patient groups.

The exact mechanism by which elevated CRP is linked to poor prognosis remains elusive. Recent studies have suggested that elevated biomarkers of systemic inflammation may merely reflect the aggressiveness of the tumor and therefore represent a consequence of established prognostic factors, such as tumor size and grade [17]. This finding is compatible with the observation that cancer patients repeatedly show higher CRP levels than healthy controls [35,36] and that patients with advanced breast cancer show elevated CRP levels as a sign of increased tumor burden [20,37]. Another hypothesis is that systemic inflammation may not solely be a consequence of tumor burden, but actively contribute to tumor progression. This view is supported by another study, describing the association between elevated CRP up to 31 months after tumor removal and shorter survival time [38].

In this study we demonstrate that marked elevation of preoperatively measured CRP level in peripheral blood is associated with shorter disease-free and overall survival in a population of untreated node-negative breast cancer, independent of well-established clinicopathological criteria. Our study has several strengths: (i) it is the first analysis of a patient population not treated with systemic adjuvant therapy which allows for assessment of the pure prognostic effect without potential predictive interactions, (ii) this analysis is – to the best of our knowledge – the first to examine the correlation of CRP values with the expression of a multitude of genes in the corresponding carcinomas of the breast. In this context, our findings reinforce the observed lack of strong correlations between CRP level in peripheral blood and well-known prognostic markers of inflammation, immune response and proliferation in the local tumor tissue environment. This finding shows that blood CRP level is an independent marker of prognosis, but also raises important concerns that systemic inflammation primarily is indicative of co-occurring disease unrelated to the primary tumor in this patient population.

Nonetheless, a number of essential limitations to this study must be considered: (i) the result is based on analysis of one relatively small single center study cohort, as no independent untreated node-negative validation cohort was available, (ii) CRP data was collected retrospectively and was measured only once for each patient, therefore being liable to fluctuations, e.g. due to acute infection, and (iii) lifestyle factors that may influence CRP levels, such as smoking habit, body mass index and comorbidities like...
diabetes or cardiovascular disease, were not taken into account, as this information was not available for the complete patient cohort. The observation that several patients among those with a marked elevation of pre-operative CRP level died because of reasons other than breast cancer may suggest that elevated CRP primarily represents the presence of concurrent disease in a small patient subset and is unrelated to primary tumor burden in node-negative breast cancer patients, further supported by the lack of correlation to tumor size and grade. In addition, no significant association was observed with metastasis-free survival, possibly suggesting that while systemic inflammation is linked to overall survival, as well as disease-free survival, it is not directly influencing tumor progression and metastasis.

In conclusion, we show that systemic inflammation, assessed by pre-operative CRP level at the time of diagnosis, may influence overall and disease-free survival in untreated node-negative patients, independent of tumor size, tumor grade, and molecular subtype. Based on large-scale gene expression analysis in a subgroup of 72 (48.6%) patients, we highlight for the first time, that circulating CRP is not related to the expression of genes in the corresponding carcinomas of the breast. Nevertheless, the proposed prognostic relevance of pre-operative CRP must be
interpreted with caution. Further large-scale prospective investigations will be necessary in order to validate the effect of systemic inflammation on breast cancer prognosis as well as the potential clinical implementation of pre-operative CRP level as a prognostic biomarker in node-negative breast cancer.

Supporting Information

Figure S1 Test of the internal stability of the models shown in Table 3 using bootstrapping. DFS: disease free survival; MFS: metastasis free Survival; OS: overall survival; HR: hazard ratio. (TIF)

Table S1 Multivariate Cox regression analysis for disease-free survival (DFS), metastasis-free survival (MFS) and overall survival (OS) based on continuous variables for CRP, age, tumor size and tumor grade. (DOC)

Table S2 Univariate Cox regression analysis for disease-free survival (DFS), metastasis-free survival (MFS) and overall survival (OS) for the non-dichotomized data of Ki67. (DOC)

Table S3 Spearman’s rank correlation coefficient between pre-operative CRP level and mRNA expression level for all probe sets on the Affymetrix HG-U133A array was assessed with the false discovery rate (0.05) controlled according to Benjamini and Yekutieli. (XLSX)

Acknowledgments

This article contains parts of the thesis of Ms. Eva Wesbuer.

Author Contributions

Conceived and designed the experiments: IS MS KE EW MJB AL CS GH JL VW MG JR JGH. Performed the experiments: IS MS KE EW MJB AL CS GH JL. Analyzed the data: IS MS KE EW MJB AL CS GH JL. Contributed reagents/materials/analysis tools: JL MS KE IS MG VW JR. Wrote the paper: IS KE MS JGH.

References

1. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420 (6917): 860–867. Available: doi:10.1038/nature01322.
2. Schmidt M, Bohm D, von Törne C, Steiner E, Puhl A, et al. (2008) The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res. 68 (13): 5405–5413. Available: doi:10.1158/0008-5472.CAN-07-3206.
3. Schmidt M, Hellessig R, Hammad S, Ohnman A, Lohr M, et al. (2012) A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin x C as a compatible prognostic marker in human solid tumors. Clin. Cancer Res. 18 (9): 2695–2703. Available: doi:10.1158/1078-0432.CCR-11-2210.
4. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, et al. (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313 (5795): 1960–1964. Available: doi:10.1126/science.1129139.
5. Laghi L, Bianchi P, Miranda E, Balladore E, Pacetti V, et al. (2009) CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol. 10 (9): 877–881. Available: doi:10.1016/S1470-2045(09)70116-X.
6. Swann JB, Smyth MJ (2007) Immune surveillance of tumors. J. Clin. Invest. 117 (5): 1137–1146. Available: doi:10.1172/JCI31405.
7. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144 (5): 646–674. Available: doi:10.1016/j.cell.2011.02.013.
8. Allin KH, Bojesen SE, Nordestgaard BG (2009) Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J. Clin. Oncol. 27 (13): 2217–2224. Available: doi:10.1200/JCO.2008.19.0448.
9. Cramley ABC, McMillan DC, McKernan M, Going JJ, Shearer CJ, et al. (2006) An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer. Br. J. Cancer 94 (11): 1568–1571. Available: doi:10.1038/sj.bjc.6603150.
10. Scott HR, McMillan DC, Forrest LM, Brown DJF, Mc Ardle CS, et al. (2002) The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br. J. Cancer 87 (3): 284–287. Available: doi:10.1038/sj.bjc.6600466.
11. Mc Ardle PA, Mir K, Almuhatat ASK, Wallace AM, Underwood MA, et al. (2006) Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer. Urol. Int. 77 (2): 127–129. Available: doi:10.1159/000093905.
12. Mortensen RF (2001) C-reactive protein, inflammation, and innate immunity. Immunol. Rev. 24 (2): 163–176. Available: doi:10.1385/IR:24:2:163.
13. Han Y, Mao F, Wu Y, Fu X, Zhu X, et al. (2011) Prognostic role of C-reactive protein in breast cancer: a systematic review and meta-analysis. Int. J. Biol. Markers 26 (4): 209–215. Available: doi:10.5301/JBM.2011.8072.
14. Al Murri AM, Wilson C, Lannigan A, Doughty JC, Angerson WJ, et al. (2007) Clinical significance of pre-operative C-reactive protein and prognosis in early-stage breast cancer. Br. J. Cancer 96 (6): 891–895. Available: doi:10.1038/sj.bjc.6603682.
15. Tibshirani R, Hastie T, Narasimhan B, Chu G (2002) Diagnosis of multiple cancer types by protein profiling. Nature 418 (6886): 868–874. Available: doi:10.1038/nature00880.
18. Albuquerque KV, Price MR, Bailey RA, Journi U, Pearson D, et al. (1995) Pretreatment serum levels of tumour markers in metastatic breast cancer: a prospective assessment of their role in predicting response to therapy and survival. Eur J Surg Oncol 21 (5): 504–509.

19. Heys SD, Ogston KN, Simpson WG, Walker LG, Hutcheon AW, et al. (1998) Acute phase proteins in patients with large and locally advanced breast cancer treated with neo-adjuvant chemotherapy: response and survival. Int. J. Oncol. 13 (3): 589–594.

20. O’Hanlon DM, Lynch J, Cormican M, Given HF (2002) The acute phase response in breast carcinoma. Anticancer Res. 22 (2B): 1289–1293.

21. Schmidt M, Victor A, Bratzel D, Boehm D, Cotoarello C, et al. (2009) Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer — comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial. Ann. Oncol. 20 (2): 258–264. Available: doi:10.1093/annonc/mdn590.

22. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19 (5): 403–410.

23. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, et al. (2006) REporting recommendations for tumor MARKer prognostic studies (RE-MARK). Breast Cancer Res. Treat. 100 (2): 229–235. Available: doi:10.1007/s10549-006-9242-8.

24. Altman DG, Andersen PK (1989) Bootstrap investigation of the stability of a Cox regression model. Stat Med 8 (7): 771–783.

25. Sauerbrei W, Schumacher M (1992) A bootstrap resampling procedure for model building: application to the Cox regression model. Stat Med 11 (16): 2093–2109.

26. Reis-Alves SC, Traina F, Harada G, Campos PM, Saad STO, et al. (2013) Immunophenotyping in myelodysplastic syndromes can add prognostic information to well-established and new clinical scores. PLoS ONE 8 (12): e81048. Available: doi:10.1371/journal.pone.0081048.

27. Ferro DP, Falconi MA, Adam RL, Ortega MM, Lima CP, et al. (2011) Fractal characteristics of May-Griswald-Giemsma stained chromatin are independent prognostic factors for survival in multiple myeloma. PLoS ONE 6 (6): e20706. Available: doi:10.1371/journal.pone.0020706.

28. Metze K (2008) Dichotomization of continuous data – a pitfall in prognostic factor studies. Pathol. Res. Pract. 204 (5): 213–214. Available: doi:10.1016/j. prp.2007.12.082.

29. Metze K (2011) Pitfalls in the assessment of prognostic factors. Lancet Oncol. 12 (12): 1095–1096. Available: doi:10.1016/S1470-2045(11)70309-6.

30. Metze K (2011) Dichotomizing continuous prognostic factors can cause paradoxical results in survival models. J. Am. Coll. Surg. 212 (1): 132–134. Available: doi:10.1016/j.jamcollsurg.2010.10.004.

31. Schmidt M, Koellh H (2012) Adjuvant chemotherapy in early breast cancer. Minerva Ginecol 64 (1): 53–63.

32. van de Vijver MJ, He XD, van’t Veer LJ, Dai H, Hart AAM, et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347 (25): 1999–2009. Available: doi:10.1056/NEJMoa021967.

33. Paik S, Shak S, Tang G, Kim C, Baker J, et al. (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351 (27): 2817–2826. Available: doi:10.1056/NEJMoa041588.

34. Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, et al. (2011) A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin. Cancer Res. 17 (18): 6012–6020. Available: doi:10.1158/1078-0432.CCR-11-0926.

35. Heikkila K, Ebrahim S, Lawlor DA (2007) A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health 61 (9): 824–833. Available: doi:10.1136/jech.2006.051292.

36. Yigit E, Gomullu G, Yucel I, Turgut M, Erdem D, et al. (2008) Relation between hematostic parameters and prognostic/predictive factors in breast cancer. Eur. J. Intern. Med. 19 (9): 602–607. Available: doi:10.1016/j.ejim.2007.06.036.

37. Robertson JF, Pearson D, Price MR, Selby C, Pearson J, et al. (1994) Prospective assessment of the role of five tumour markers in breast cancer. Cancer Immunol. Immunother. 35 (6): 403–410.

38. Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhouser ML, et al. (2009) Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J. Clin. Oncol. 27 (21): 3437–3444. Available: doi:10.1200/JCO.2008.18.9068.